Final Prospectus

Final Prospectus

1. The last prospectus distributed prior to a new issue of a security. The final prospectus contains similar information to a preliminary prospectus, but is updated, and, importantly, contains the security's price.

2. The most recent prospectus distributed by a mutual fund. Mutual funds update their prospecti from time to time as the types of securities represented in the fund, or perhaps its investment philosophy, change. The final prospectus is issued annually.
Mentioned in ?
References in periodicals archive ?
A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC's website located at http://www.sec.gov.
A final prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website located at http://www.sec.gov.
Also, the company will file a final prospectus with the US Securities and Exchange Commission for the offering, it added.
The company has submitted a final prospectus with the US securities regulator for the offering, envisaging the placement of 24,324,400 shares at a price of USD1.85 (EUR1.43) each and gross proceeds of USD45m.
A copy of the final prospectus relating to the offering will be filed with the Securities and Exchange Commission, and may be obtained, when available, from Morgan Stanley & Co.
In conjunction, Lincoln is obligated to purchase up to an additional USD15m common stock from Onconova, subject to certain limitations, from time to time, over the 36-month period commencing on the date that a registration statement with the Securities and Exchange Commission is declared effective and a final prospectus is filed.
Copies of the final prospectus relating to this offering may be obtained by contacting Dawson James Securities, Inc., Attention: Prospectus Department, 1 North Federal Highway, 5th Floor, Boca Raton, FL 33432, mmaclaren@dawsonjames.com or toll free at 866.928.0928, or by accessing the SECs website at www.sec.gov.
The company has provided the underwriters of the offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase an additional 3,603,603 ordinary shares.
The offering of the notes will be made only by means of a prospectus included in that registration statement, the preliminary prospectus supplement and the final prospectus, when available.
The company said it intends to provide the underwriters of the offering with an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase an additional USD262.5m of ordinary shares at the public offering price, less the underwriting discounts and commissions.
The final prospectus supplement relating to and describing the terms of the offering and the accompanying prospectus will be filed with the SEC and will be available on the Securities and Exchange Commission's website at www.sec.gov.
Valeant Pharmaceuticals added that it has granted to the underwriter of the offering an option, exercisable for a period of 30 days following the date of the final prospectus supplement, to purchase additional common shares equal to up to 15% of the common shares initially sold.

Full browser ?